Related Experiment Video

Updated: Nov 18, 2025

Detection of a Circulating MicroRNA Custom Panel in Patients with Metastatic Colorectal Cancer
08:12

Detection of a Circulating MicroRNA Custom Panel in Patients with Metastatic Colorectal Cancer

Published on: March 14, 2019

5.8K

MicroRNA-Based Therapeutics for Drug-Resistant Colorectal Cancer

Eunsun Jung1, Jinhyeon Choi1, Jang-Seong Kim1

  • 1Korea Research Institute of Bioscience and Biotechnology (KRIBB), Daejeon 34141, Korea.

Pharmaceuticals (Basel, Switzerland)
|February 11, 2021
PubMed

Insights

Drug resistance remains a challenge in colorectal cancer (CRC) treatment. MicroRNAs (miRNAs) show potential as biomarkers and therapeutic targets for overcoming this resistance.

Area of Science:

  • Oncology
  • Molecular Biology
  • Genetics

Background:

  • Colorectal cancer (CRC) therapy faces persistent challenges due to drug resistance.
  • Mechanisms of drug resistance include altered drug uptake, target modification, and cell cycle deregulation.

Purpose of the Study:

  • To review recent discoveries on microRNAs (miRNAs) involved in CRC drug resistance.
  • To explore the molecular mechanisms of these miRNAs and their target genes.
  • To discuss the clinical applications of miRNAs as biomarkers and therapeutic targets in CRC.

Main Methods:

  • Literature review of studies on miRNAs and drug resistance in colorectal cancer.
  • Analysis of molecular mechanisms underlying miRNA-mediated drug resistance.
  • Discussion of current challenges and future prospects for clinical translation.

Main Results:

  • Several microRNAs (miRNAs) are implicated in resistance to chemotherapy, targeted therapy, and immunotherapy in CRC.
  • These miRNAs regulate key genes associated with drug resistance.
  • miRNAs demonstrate potential as predictive biomarkers for drug response.

Conclusions:

  • MicroRNAs (miRNAs) play a significant role in the development of colorectal cancer drug resistance.
  • Targeting specific miRNAs offers a promising strategy for overcoming drug resistance in CRC.
  • Further research is needed to address challenges in the clinical application of miRNAs for CRC treatment.
Keywords:
anti-cancer drug resistancechemoresistancecolorectal cancerimmunotherapymicroRNAtargeted therapy

More Related Videos

Monitoring of Nanodrug Accumulation in Murine Breast Cancer Metastases09:48

Monitoring of Nanodrug Accumulation in Murine Breast Cancer Metastases

Published on: August 23, 2024

610
MicroRNA Amplification and Recognition through Locked-nucleic-acid In situ Hybridization as A Novel Detection and Quantification Method09:06

MicroRNA Amplification and Recognition through Locked-nucleic-acid In situ Hybridization as A Novel Detection and Quantification Method

Published on: October 7, 2025

140

Related Concept Videos

MicroRNAs01:22

MicroRNAs

MicroRNA (miRNA) are short, regulatory RNA transcribed from introns (non-coding regions of a gene) or intergenic regions (stretches of DNA present between genes). Several processing steps are required to form biologically active, mature miRNA. The initial transcript, called primary miRNA (pri-mRNA), base-pairs with itself, forming a stem-loop structure. Within the nucleus, an endonuclease enzyme, called Drosha, shortens the stem-loop structure into hairpin-shaped pre-miRNA. After the pre-miRNA...
3.4K
MicroRNAs01:22

MicroRNAs

MicroRNA (miRNA) are short, regulatory RNA transcribed from introns—non-coding regions of a gene—or intergenic regions—stretches of DNA present between genes. Several processing steps are required to form biologically active, mature miRNA. The initial transcript, called primary miRNA (pri-mRNA), base-pairs with itself forming a stem-loop structure. Within the nucleus, an endonuclease enzyme, called Drosha, shortens the stem-loop structure into hairpin-shaped pre-miRNA. After...
23.1K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
8.1K
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.5K
Drugs that Stabilize Microtubules01:15

Drugs that Stabilize Microtubules

Microtubules are dynamic structures that undergo cycles of catastrophe and rescue. The microtubules play a central role in cell division by forming the spindle apparatus for segregating the chromosomes. This makes them ideal targets for regulating dividing cells in tumors and malignant cancer cells. Microtubule stabilizing drugs help stabilize the microtubule formation and promote its polymerization. Paclitaxel was the first microtubule stabilizing agent used as anticancer drug in chemotherapy...
2.3K
Experimental RNAi02:15

Experimental RNAi

RNA interference (RNAi) is a cellular mechanism that inhibits gene expression by suppressing its transcription or activating the RNA degradation process. The mechanism was discovered by Andrew Fire and Craig Mello in 1998 in plants. Today, it is observed in almost all eukaryotes, including protozoa, flies, nematodes, insects, parasites, and mammals. This precise cellular mechanism of gene silencing has been developed into a technique that provides an efficient way to identify and determine the...
6.8K